Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Patent
1998-10-19
2000-10-17
Azpuru, Carlos A.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
A61F 202
Patent
active
061327530
ABSTRACT:
Methods for treating specific patient groups for sexual dysfunction are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions in patients who are free of cardiac disease and/or who have not been given organic nitrates.
REFERENCES:
patent: 1897423 (1933-02-01), Ferri
patent: 2584166 (1952-02-01), Stevenson et al.
patent: 2696209 (1954-12-01), Varaney
patent: 3373746 (1968-03-01), White et al.
patent: 4311707 (1982-01-01), Birnbaum et al.
patent: 4478822 (1984-10-01), Haslam et al.
patent: 4610868 (1986-09-01), Fountain et al.
patent: 4640912 (1987-02-01), Hausman
patent: 4746508 (1988-05-01), Carey et al.
patent: 4801587 (1989-01-01), Voss
patent: 4829991 (1989-05-01), Boeck
patent: 5011931 (1991-04-01), MacLean et al.
patent: 5079264 (1992-01-01), MacLean et al.
patent: 5270323 (1993-12-01), Milne, Jr. et al.
patent: 5447912 (1995-09-01), Gerstenberg et al.
patent: 5474535 (1995-12-01), Place et al.
patent: 5492911 (1996-02-01), Stief
patent: 5721238 (1998-02-01), Heiker
patent: 5773457 (1998-06-01), Nahoum
McMurry, Organic Chemistry, 2nd Ed., Brooks/Cole Publishing, Belmont, CA (1988), pp. 1044-1045 and 1076.
Kelso, et al., "Actions of the Novel Vasodilator, Flosequinan, in Isolated Ventricular Cardiomyocytes," J. Cardiovasc. Pharmacol. 25:376-386 (1995).
Perreault, et al., "Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure," Br. J. Pharmacol. 106:511-516 (1992).
Jones, et al., "Effect of flosequinan on ischaemia-induced arrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat," Br. J. Pharmacol. 108:1111-1116 (1993).
Gristwood, et al., "Studies on the cardiac actions of flosequinan in vitro," Br. J. Pharmacol. 105:985-991 (1992).
Frodsham, et al., "Effect of flosequinan upon isoenzymes of phosphodiesterase from guinea-pig cardiac and vascular smooth muscle," Eur. J. Pharmacol. 211:383-391 (1992).
Delcour, et al., "Impotence: Evaluation with Cavernosography," Radiology 161:803-806 (1986).
Porst et al., "Relevance of Dynamic Cavernosography to the Diagnosis of Venous Incompetence in Erectile Dysfunction," J. Urol. 137:1163-1167 (1987).
Lue et al., "Physiology of Erection and Pharmacological Management of Impotence," J. Urol. 37:829-836 (1987).
Garban et al., "Effect of aging on nitric oxide-mediated penile erection in rats," Am. J. Phys. 46:H467 (1995).
Raifer et al., "Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission," New Engl. J. Med. 326:90 (1992).
Boolel et al., "Slidenafil, a novel effective oral therapy for male erectile dysfunction," Br. J. Ur. 78:257 (1996).
Silver et al., "Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isoenzymes isolated from cardiac muscle, arterial and airway smooth muscle," European J. Pharmacology, 150:85-94 (1988).
Kauffman et al., "Characterization and Pharmacological Relevance of High Affinity Binding Sites for [.sup.3 H]LY186126, a Cardiotonic Phosphodiesterase Inhibitors, in Canine Cardiac Membranes," Circulation Research, 65(1):154-163.
Park et al., "Vasculogenic female sexual dysfunction: The hemodynamic basis for vaginal engorgement insufficiency and clotoral erectile insufficiency," Int. J. Impotence Res., 9:27-37 (1997).
Malhotra et al., "Cavernosography in Conjunction with Artificial Erection for Evaluation of Venous Leakage in Impotent Men," Radiology, 161:799-802 (1986).
Dawson et al., "Cliostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial," Circulation, 98(7):678-86 (1998).
Minami et al., "Inhibition of shear stree-induced platelet aggregation by cilostazol, a specific inhibitor of cgmp-inhibited phosphodiesterase, in vitro and ex vivo," Life Sciences, 61(25):PL 383-389 (1997).
Shiraishi et al., "Effect of cilostazol, a phosphodiesterase type III inhibitor, ON Histamine-induced increase in [Ca2+]i and force in middle cerebral artery of the rabbit," Br. J. Pharmacol., 123(5):869-878 (1997).
Azpuru Carlos A.
Cutler Neal R.
LandOfFree
Treatment of sexual dysfunction in certain patient groups does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of sexual dysfunction in certain patient groups, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of sexual dysfunction in certain patient groups will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-465900